Last reviewed · How we verify
WEZLANA (USTEKINUMAB-AUUB)
WEZLANA (generic name: USTEKINUMAB-AUUB) is a Interleukin-12 Antagonist [EPC] drug developed by AMGEN INC. It is currently FDA-approved for Moderate to Severe Plaque Psoriasis, Active Psoriatic Arthritis, Moderately to Severely Active Crohn's Disease.
Wezalana is an interleukin-12 inhibitor, classified as an antibody drug. It is also known by the synonyms CNTO 1275, CNTO-1275, PYZCHIVA, SELARSDI, STELARA, and STELERA.
At a glance
| Generic name | USTEKINUMAB-AUUB |
|---|---|
| Sponsor | AMGEN INC |
| Drug class | Interleukin-12 Antagonist [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Moderate to Severe Plaque Psoriasis
- Active Psoriatic Arthritis
- Moderately to Severely Active Crohn's Disease
- Moderately to Severely Active Ulcerative Colitis
Common side effects
- Infections
- Malignancies (excluding non-melanoma skin cancer)
- Non-melanoma skin cancer
Serious adverse events
- Serious infections
- Serious infections (placebo-controlled period)
- PRES (Posterior Reversible Encephalopathy Syndrome)
- Cellulitis
- Herpes zoster
- Diverticulitis
Drug interactions
- immunosuppressive agents
- phototherapy
- methotrexate (MTX)
- 6-mercaptopurine (6-MP), azathioprine (AZA), methotrexate (MTX)
- corticosteroids
- CYP450 substrates
- allergen immunotherapy
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WEZLANA CI brief — competitive landscape report
- WEZLANA updates RSS · CI watch RSS
- AMGEN INC portfolio CI
Frequently asked questions about WEZLANA
What is WEZLANA?
WEZLANA (USTEKINUMAB-AUUB) is a Interleukin-12 Antagonist [EPC] drug developed by AMGEN INC, indicated for Moderate to Severe Plaque Psoriasis, Active Psoriatic Arthritis, Moderately to Severely Active Crohn's Disease.
What is WEZLANA used for?
WEZLANA is indicated for Moderate to Severe Plaque Psoriasis, Active Psoriatic Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis.
Who makes WEZLANA?
WEZLANA is developed and marketed by AMGEN INC (see full AMGEN INC pipeline at /company/amgen).
What is the generic name of WEZLANA?
USTEKINUMAB-AUUB is the generic (nonproprietary) name of WEZLANA.
What drug class is WEZLANA in?
WEZLANA belongs to the Interleukin-12 Antagonist [EPC] class. See all Interleukin-12 Antagonist [EPC] drugs at /class/interleukin-12-antagonist-epc.
What development phase is WEZLANA in?
WEZLANA is FDA-approved (marketed).
What are the side effects of WEZLANA?
Common side effects of WEZLANA include Infections, Malignancies (excluding non-melanoma skin cancer), Non-melanoma skin cancer. Serious adverse events: Serious infections, Serious infections (placebo-controlled period), PRES (Posterior Reversible Encephalopathy Syndrome), Cellulitis.
Related
- Drug class: All Interleukin-12 Antagonist [EPC] drugs
- Manufacturer: AMGEN INC — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Moderate to Severe Plaque Psoriasis
- Indication: Drugs for Active Psoriatic Arthritis
- Indication: Drugs for Moderately to Severely Active Crohn's Disease